Auxilium Pharmaceuticals (NASDAQ:AUXL): Closing price $18.05
On Monday, the specialty biopharmaceutical firm announced positive data for collagenase clostridium histolyticum which is being developed for the potential treatment, upon approval by the FDA, of adult patients suffering from adhesive capsulitis, commonly known as Frozen Shoulder syndrome. FSS is a common, prolonged, painful condition of the shoulder, thought to be caused by increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint, leading to a loss of range of motion in the shoulder. This condition is believed to affect about two to five percent of the general adult population and the full duration of the disease can last from around 1 year to up to 3.5 years.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.